SynthesisOncotarget2017
Predictive value of glucose transporter-1 and glucose transporter-3 for survival of cancer patients: A meta-analysis.
Synthesis in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Pooled it
- Associations between GLUT expression and SUV values derived from FDG-PET in different tumors-A systematic review and meta analysis.PloS one · 2019Pooled it
- Clinicopathological and prognostic significance of GLUT1 in breast cancer: A meta-analysis.Medicine · 2018Pooled it
- Pooled it
- Glucose Transporter 1 in Health and Disease.MedComm · 2026Review
- Dynamic evaluation of the glycolytic determinants LDH-A and GLUT-1 enhances prognostic significance and their inhibition affects the growth of mesothelioma spheroids.Molecular metabolism · 2026Article
- Glucose-transporter 1 (GLUT1) as a prognostic biomarker: evidence from 14,966 human tumors across 134 cancer types.BMC cancer · 2026Article
- Transcriptional Expression of SLC2A3 and SDHA Predicts the Risk of Local Tumor Recurrence in Patients with Head and Neck Squamous Cell Carcinomas Treated Primarily with Radiotherapy or Chemoradiotherapy.International journal of molecular sciences · 2025Article
- Rg3-lipo biomimetic delivery of paclitaxel enhances targeting of tumors and myeloid-derived suppressor cells.The Journal of clinical investigation · 2024Article
- Oxidative stress regulation and related metabolic pathways in epithelial-mesenchymal transition of breast cancer stem cells.Stem cell research & therapy · 2023Review
- MicroRNAs-mediated regulation of glucose transporter (GLUT) expression in glioblastoma.Non-coding RNA research · 2022Review
- Review
- Review
- Crosstalk between Hypoxia and Extracellular Matrix in the Tumor Microenvironment in Breast Cancer.Genes · 2022Review
- Identification of stromal microenvironment characteristics and key molecular mining in pancreatic cancer.Discover oncology · 2022Article
- Glucose transporters as markers of diagnosis and prognosis in cancer diseases.Oncology reviews · 2022Article
- Androgen-Dependent Prostate Cancer Cells Reprogram Their Metabolic Signature upon GLUT1 Upregulation by Manganese Superoxide Dismutase.Antioxidants (Basel, Switzerland) · 2022Article
- Review
- Article
- Potential Role of Glucose Transporter-1 Expression in Gastric Cancer: A Meta-Analysis and Systematic Review.Iranian journal of public health · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveThe role of glucose transporters in cancers remains contradictory. We conducted a systematic review and meta-analysis to assess the association between overall survival and glucose transporter s (GLUTs) 1 and 3 to find an accurate prognostic biomarker.
methodsWe systematically searched the PubMed, EMbase and Medline databases for relevant published studies that were consistent with the eligible criteria up to January 2016, and calculated pooled estimated hazard ratios of GLUT-1 and -3's expressions in different cancer types and ethnic populations. Random-effects models were used to assess estimates from studies with significant heterogeneities.
resultsOverall, 12 studies concerning GLUT 1 and 2 studies concerning GLUT 3, which involved 2008 participants when combined, were included in this analysis. We found that overexpression of GLUTs were significantly correlated to poorer survival rates (HR=1.63, 95%CI=1.09-2.44 and HR=1.89, 95%CI=1.28-2.81). In the subgroup analysis, the GLUT 1 up-regulation was correlated with negative overall survival in pancreatic cancer and gastric cancer and with better overall survival in colorectal cancer. In addition, overexpression of GLUT 1 was associated with a poorer prognosis in the Asian population, while no significance was found in the non-Asian subgroup. However, limitations do exist, which could be handled better.
conclusionsA combination of GLUTs 1 and 3 might help predict malignancy of cancers and direct effective cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.